Human cytomegalovirus-mediated immunomodulation: Effects on glioblastoma progression

Haidn Foster, Ilya V. Ulasov*, Charles S. Cobbs

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


The presence of human cytomegalovirus (HCMV) and glioblastoma multiforme (GBM), first established in 2002, has developed into an area of considerable interest and controversy. Numerous studies have found evidence of possible HCMV infection of GBM tumor cells as well as myriad onco- and immunomodulatory properties exhibited by HCMV antigens and transcripts, while recent reports have failed to detect HCMV particles in GBM and question the virus' role in tumor progression. This review highlights the known immunomodulatory properties of HCMV, independent of GBM infection status, that help drive the virus from peripheral blood into the vital tissues and subsequently dampen local immune response, assisting GBM tumors in evading immune surveillance and contributing to the disease's poor prognosis. Emerging antiviral approaches to treating GBM, including antiviral drugs and immunotherapies directed against HCMV, are also examined.

Original languageEnglish (US)
Pages (from-to)273-276
Number of pages4
JournalBiochimica et Biophysica Acta - Reviews on Cancer
Issue number1
StatePublished - Aug 2017


  • Glioblastoma multiforme
  • Human cytomegalovirus
  • Immunosuppression

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research


Dive into the research topics of 'Human cytomegalovirus-mediated immunomodulation: Effects on glioblastoma progression'. Together they form a unique fingerprint.

Cite this